Skip to main content
. 2023 Jul 28;72(12):2307–2320. doi: 10.1136/gutjnl-2022-329147

Figure 6.

Figure 6

Targeted MS4A4A treatment synergises with anti-PD-1 mAb treatment. (A–F) Tumour growth of CT26 tumour-bearing mice treated with an isotype control, an anti-PD-1 mAb, an anti-MS4A4A mAb or the anti-PD-1 mAb combined with the anti-MS4A4A mAb (n=5/group). (A) Schematic showing the treatment plan. (B–D) Tumour growth. (E) Survival of CT26 tumour-bearing mice. (F) Body weight of mice in each group. (G–L) Tumour growth of B16F10 tumour-bearing mice treated with an isotype control, an anti-PD-1 mAb, an anti-MS4A4A mAb or the anti-PD-1 mAb combined with the anti-MS4A4A mAb (n=5–6/group). (G) Schematic showing the treatment plan. (H–J) Tumour growth. (K) Tumour weight. (L) Body weight of mice in each group. (M–O) Mouse CT26 colon cancer cells were injected in situ into the cecum wall of mice and then treated with an isotype control, an anti-PD-1 mAb, an anti-MS4A4A mAb or the anti-PD-1 mAb combined with the anti-MS4A4A mAb (n=5/group). (M) Schematic showing the treatment plan. (N) Macroscopic appearance of orthotopic CRC tumours for each indicated treatment. (O) Tumour volume. (P) Tumour growth curves of mice rechallenged s.c. as in (E) (survivor) (n=3) with MC38 cells and age-matched tumour-naive mice (control) (n=5). (Q) Overall survival of rechallenged mice depicted with a Kaplan-Meier curve (n=3–5/group). (R) Representative images and statistical analysis of immunohistochemical staining for MS4A4A in tumour samples from patients with CRC (n=12) who underwent surgical resection or colonoscopic biopsy prior to immunotherapy. Five random high-power fields were selected for analysis on each slide. (S) Kaplan-Meier plots showing the relationships between the level of MS4A4A gene expression in tumours and the overall survival or progression-free survival of patients with cancer treated with anti-PD-L1 therapy in a cohort of patients with oesophageal cancer. (T) Kaplan-Meier plots showing the relationships between the level of MS4A4A gene expression in tumours and the overall survival or progression-free survival of patients with cancer treated with anti-PD-1 therapy in a cohort of patients with bladder cancer, patients with glioblastoma or patients with melanoma. CRC, colorectal cancer; i.p., intraperitoneal injection; mAb, monoclonal antibody; PD-1, programmed cell death protein 1; s.c., subcutaneous.